Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sagimet Biosciences, Inc. Class A ( (SGMT) ) is now available.
Sagimet Biosciences reported its fourth-quarter and full-year 2025 results on March 11, 2026, highlighting clinical progress across its MASH and acne portfolios and solid liquidity of $113.1 million in cash, cash equivalents and marketable securities at year-end. The company completed a Phase 1 pharmacokinetic trial of denifanstat combined with thyroid hormone receptor beta agonist resmetirom with no safety signals and plans to advance this combination into a Phase 2 proof-of-concept trial in F4 MASH in the second half of 2026, while continuing a Phase 1 trial of acne-targeted FASN inhibitor TVB-3567.
In parallel, Sagimet strengthened its combination strategy via a global, exclusive license to innovative resmetirom active pharmaceutical ingredient forms from TAPI and benefited from partner Ascletis’ positive 52-week Phase 3 acne data and China NMPA acceptance of a New Drug Application for denifanstat in moderate to severe acne. Financially, 2025 research and development expenses were $39.1 million and net loss widened to $51.0 million, reflecting an intensified development program that could enhance the company’s position in high-need liver and dermatology markets if upcoming Phase 2 trials and regulatory pathways progress as planned.
The most recent analyst rating on (SGMT) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.
Spark’s Take on SGMT Stock
According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and significant ongoing cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting this, recent positive clinical and pipeline-related corporate events provide meaningful upside potential, while valuation offers limited support due to a negative P/E and no dividend.
To see Spark’s full report on SGMT stock, click here.
More about Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors targeting dysfunctional metabolic and fibrotic pathways, particularly in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne. Its lead oral, once-daily FASN inhibitor denifanstat has met primary endpoints in a Phase 2b trial in MASH and in a partner-led Phase 3 acne trial in China, while its second FASN inhibitor TVB-3567 is in a first-in-human Phase 1 trial for acne.
Average Trading Volume: 622,604
Technical Sentiment Signal: Hold
Current Market Cap: $171.4M
For detailed information about SGMT stock, go to TipRanks’ Stock Analysis page.